Bradford Navia

Affiliation:Aprinoia therapeutics LLC Massachusetts

Link to group website: Website

Bio

Bradford Navia, MD, PhD is the Chief Medical Officer, Executive Vice President and global head of R&D at Aprinoia Therapeutics, Cambridge, MA, a clinical stage biotechnology company, which aims to develop novel imaging agents to detect tau and alpha synuclein in patients with neurodegenerative disorders in addition to therapeutics that includes biologics and small molecules targeting these proteins.

Prior to joining Aprinoia, Dr Navia had spent 15 years in industry in various roles with increasing responsibility (Johnson and Johnson, Eisai, where he was the global head of imaging, AbbVie and at Sunovion). He has extensive leadership experience in imaging and clinical development in neurology and psychiatry, where his work spanned early and late-stage clinical development programs in Parkinson’s Disease, Alzheimer’s Disease, ALS, retinitis pigmentosa, schizophrenia, major depression, and binge eating disorder. He successfully led several phase1 to 3 trials for these indications and at Sunovion, he was the Global Project Lead for APL-130277, a sublingual formulation of apomorphine) approved in the US and Canada for the treatment of OFF episodes in Parkinson’s Disease. He was also the clinical lead for early-stage stem cell programs for the treatment of retinitis pigmentosa (Sunovion) and stroke (JNJ).

Dr. Navia brings 15 years of academic experience in basic and clinical research at Massachusetts General Hospital, Harvard University and Tufts University Medical and Graduate School where he was an Associate Professor in the Departments of Neurology & Psychiatry, Public Health, and Neuroscience. He has been internationally recognized for the discovery of NeuroAIDS and advances in neuroimaging, including developing one of the first imaging biomarker consortia in the US. He was the recipient of extensive grant funding from NIH as principal or co-principal investigator and has authored nearly five hundred publications, abstracts, and chapters. He has served on various committees for NIH, ADNI, and CAMD.

He received his medical degree at Columbia College of Physicians and Surgeons, neurology training at Cornell, NY and his doctoral degree in neuroscience and genetics at Harvard University, Cambridge, MA.